Novo Nordisk to discontinue Levemir insulin in U.S. market

Celebrating Wild Caraway: Taste of Nova Scotia's Restaurant of the Year | SaltWire - Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir, in response to mounting political pressure over insulin prices. The announcement followed a similar one by Eli Lilly.

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Novo Nordisk to discontinue Levemir insulin in U.S. marketThe Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir...
مصدر: YahooFinanceCA - 🏆 47. / 63 اقرأ أكثر »

Factbox-Corporate America weighs business impact of new weight-loss drugsDrugs in a class known as GLP-1 such as Novo Nordisk's Wegovy and Ozempic as well as Eli Lilly's Mounjaro have been shown to help control blood sugar and...
مصدر: YahooFinanceCA - 🏆 47. / 63 اقرأ أكثر »